Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2Genitourinary 1

Conditions

Breast Neoplasms 89Neoplasms 6HER2-positive Breast Cancer 5Triple Negative Breast Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Carcinoma, Non-Small-Cell Lung 4Stomach Neoplasms 3Neoplasm Metastasis 3Multiple Myeloma 3Colorectal Neoplasms 3Urinary Bladder Neoplasms 2Rectal Neoplasms 2Pathologic Complete Response 2Pancreatic Neoplasms 2Lymphoma, Non-Hodgkin 2Lung Neoplasms 2Locally Advanced Breast Cancer 2Inflammatory Breast Neoplasms 2Colonic Neoplasms 2Brain Neoplasms 2Biliary Tract Neoplasms 2Anatomic Stage I Breast Cancer AJCC v8 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Cancers 1Salivary Gland Neoplasms 1Neuroendocrine Tumors 1Neuroblastoma 1

Interventions

Gemcitabine 45Cisplatin 34Oxaliplatin 23Capecitabine 17Fluorouracil 13Leucovorin 12pembrolizumab 11lenvatinib 11durvalumab 10S 1 (combination) 10Irinotecan 10Bevacizumab 9apatinib 7Nivolumab 7tremelimumab 6Trastuzumab 5envafolimab 4atezolizumab 4Injections 4Docetaxel 4trametinib 3titanium silicide 3tislelizumab 3irinotecan sucrosofate 3camrelizumab 3Radiotherapy 3Drug Therapy 3zanidatamab 2toripalimab 2surufatinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Biliary Tract Neoplasms × pertuzumab × Clear all
NCT07129018 2025-08-19

Trastuzumab Rezetecan Combined With Pertuzumab and Iparomlimab and Tuvonralimab for Biliary Tract Cancer

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

Phase 2 Not yet recruiting
63 enrolled
Gastrointestinal

Biliary Tract Neoplasms

NCT02091141 2024-07-23

My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors

Genentech, Inc.

Phase 2 Completed
673 enrolled 22 charts
GastrointestinalGenitourinary

Biliary Tract Neoplasms, Urinary Bladder Neoplasms, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡